Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Medical oncology].

M S Aapro1

  • 1Clinique de Genolier, 1272 Genolier. maapro@genolier.net

Revue Medicale Suisse
|March 16, 2007
PubMed
Summary

The 2006 medical oncology landscape showed less promise than 2005, but new targeted cancer therapies like sunitinib and sorafenib offer hope for renal cell cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

[Society face to cancer: awareness and social actions].

Revue medicale suisse·2015
Same author

Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

Cancer treatment reviews·2012
Same author

What do prescribers think of biosimilars?

Targeted oncology·2012
Same author

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

European journal of cancer (Oxford, England : 1990)·2010

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Context:

  • The year 2006 presented challenges in medical oncology, with a general decrease in enthusiasm compared to 2005.
  • Advances in targeted therapies are emerging as a significant development in cancer treatment.

Purpose:

  • To review recent developments and identify areas for improvement in cancer treatment strategies.
  • To highlight specific agents showing promise in improving patient outcomes for renal cell carcinoma.

Summary:

  • Despite a general decline in enthusiasm in medical oncology in 2006, targeted therapies such as sunitinib and sorafenib have shown significant benefits for patients with renal cell cancer.
  • The reviewed literature emphasizes the critical need for more precise cancer treatment approaches, including chemotherapy, to enhance efficacy and minimize toxicity.

Impact:

  • The development and marketing of sunitinib and sorafenib represent a notable exception, offering improved outcomes for renal cell cancer patients.
  • Future advancements in targeted cancer therapy are anticipated to increase treatment effectiveness and reduce patient exposure to unnecessary toxicity.

Related Experiment Videos